In the second quarter of the fiscal year ending December 2026, all categories achieved double-digit Year-over-Year growth. Strong sales from SALONIA and growth in the health supplement brand portfolio are expected to drive higher-than-anticipated revenue and profit. A full-year upward revision has been made. In the second half, while continuing additional investments, the company will factor in profit pressure drivers (costs, FX, investments) and advance measures to prevent recurrence.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4933","jir_company_name":"I-ne CO., LTD.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4933-20260930-01.pdf","jir_short_summary":"In the second quarter of the fiscal year ending December 2026, all categories achieved double-digit Year-over-Year growth. Strong sales from SALONIA and growth in the health supplement brand portfolio are expected to drive higher-than-anticipated revenue and profit. A full-year upward revision has been made. In the second half, while continuing additional investments, the company will factor in profit pressure drivers (costs, FX, investments) and advance measures to prevent recurrence.","jir_summary":"### Business Performance Overview\nIn the second quarter of the fiscal year ending December 2026, all categories achieved double-digit Year-over-Year growth, resulting in companywide revenue and profit that exceeded expectations. Growth drivers included the health supplement brand portfolio launched in 2025 and a major hit from SALONIA\u2019s face current pointer. On this basis, full-year guidance was revised upward by +3,000 million yen for net sales and +500 million yen each for EBITDA and operating income.\n\n### Investment Plan and Outlook\nAdditional investments in the second half are planned at approximately 3,000\u20134,000 million yen, and approximately 1,400 million yen was invested in the first half for advertising and promotion. Due to the growth of the health supplement brand portfolio and the strong performance of new beauty appliance products, some of the profit pressure from the additional investments has been offset. In the second half, the company will continue to flexibly invest across categories from the perspective of enhancing mid- to long-term corporate value.","jir_financial_highlights":"Net Sales: Unknown (Double-digit Year-over-Year growth)\nEBITDA: Unknown (Upward revision made)\nOperating Income: Unknown (Upward revision made)","jir_category":"","jir_hashtags":"#I-ne, #earnings, #sales_growth, #SALONIA_hit, #health_supplement_brand_portfolio, #additional_investment","jir_key_figures":"Net Sales: Unknown\nEBITDA: Unknown\nOperating Income: Unknown","jir_meta_title":"I-ne CO., LTD. \u2014 Q2 Financial Results for Fiscal Year Ending December 2026 | Key Points on Sales Growth and Upward Revision","jir_meta_description":"Summary of Q2 results for the fiscal year ending December 2026. Double-digit growth across all categories driven by SALONIA and the health supplement brand portfolio. Explains the full-year upward revision, second-half investment policy, and progress on prevention measures.","jir_og_title":"I-ne CO., LTD. \u2014 Key Points from Q2 Financial Results for Fiscal Year Ending December 2026","jir_og_description":"Achieved double-digit growth across all categories; full-year upward revision driven by SALONIA\u2019s success. Investment will continue in the second half while advancing prevention measures.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":57641,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-125039","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n